Patients with generalized myasthenia gravis (gMG), a rare and chronic autoimmune disease, experience severe fatigue and muscle weakness that negatively impact their daily lives. Greater understanding of the complex pathophysiology of gMG has led to a rapidly evolving treatment landscape, including targeted therapies providing a more individualized and effective approach. Neonatal Fc receptor (FcRn) antagonists are the latest class of medications to receive approval for gMG, and several recent phase 3 trials are likely to result in a greater selection of available FcRn-targeting therapies. In this first of two videos, join two experts in a discussion covering the pathophysiology of gMG, current treatment modalities and management strategies, and an in-depth look at the role of FcRn antagonism, including evaluation of the latest clinical evidence for approved and emerging FcRn antagonists. You will also gain immediate access to downloadable evidence and a concise, point-of-care resource to reference in your daily practice. This activity is delivered in partnership with the Muscular Dystrophy Association (MDA).
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/fcrn-antagonists-transformative-potential-treating-generalized-myasthenia-gravis
- Start Date: 2024-08-29 05:00:00
- End Date: 2024-08-29 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - Commercial Support: Source: Janssen (Any division) - Amount: 62500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all